BioSpace News Archive

BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, and affiliate QED Therapeutics today announced that the U.S. food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for infigratinib,

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has named Peter P. Pfreundschuh as its new chief financial officer

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced a keynote lecture, an oral presentation and two posters at the 7 th European Scientific Working Group on Influenza (ESWI) Influenza Conference, which takes place virtually Dec. 6-9, 2020. The Keynote Lecture highlights Cidara’s Cloudb

IJSS-published review finds that the novel biplanar expandable cage provides effective vertebral body slip or spondylolisthesis reduction and improvement in radiographic and clinical parameters with no reported subsidence, migration, or endplate violation

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of its 2020 Annual Meeting of Stockholders to be held on Thursday, December 3, 2020, beginning at 11:00 a.m. EST. The Annual Meeting of Stockholders and webcast can be accessed via www.virtualshareholdermeeti

A recent publication demonstrated procedural efficiency for MitraClip™ transcatheter mitral valve repair with use of the VersaCross® RF Transseptal Solution, reporting guide delivery from femoral access in under 7.5 minutes1.

Rapidand substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response), and sustained over 12 months

Molecular Imaging Platform Leverages Hyb & Seq Chemistry to Spatially Profile Expression of 1,000+ Genes at Single Cell and Sub-Cell Resolution Across Tissue Samples

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Spain’s Vall d´Hebron Institute of Oncology (VHIO) has joined Caris’ Precision Oncology Alliance™ (The Alliance/POA)

Ra Medical Systems, Inc. is hosting a webcast, The Inimitable Role of Excimer Lasers During the COVID-19 Pandemic, featuring Theodore J. Daly, MD, FAAD, FSPD, FASD, Director of Garden City Dermatology, discussing the use of excimer lasers such as the Pharos excimer laser system for the treatment of psoriasis during the pandemic.